Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 31 peer-reviewed journal articles Updated
Medical Genetics · Tuberous Sclerosis Complex

When Is Genetic Testing Recommended for TSC and Kidney AMLs?

At a Glance

Multiple or bilateral kidney angiomyolipomas should prompt evaluation for tuberous sclerosis complex and possible TSC1/TSC2 genetic testing. A negative blood test does not always rule out TSC, so clinical assessment and ongoing screening of other organs may still be needed.

In this answer

6 sections

01

What Does the Genetic Test Look For?

02

Understanding Your Results

03

Clinical Diagnosis vs. Genetic Testing

04

Why Testing Matters: Screening Other Organs

05

Family Testing and Counseling

06

Privacy and Insurance Considerations

If you have multiple or bilateral (in both kidneys) renal angiomyolipomas (AMLs), medical guidelines strongly recommend being evaluated for Tuberous Sclerosis Complex (TSC) [1][2]. While a single, isolated AML is common in the general population, having multiple kidney AMLs is considered a major hallmark of TSC [3].

AMLs are benign (non-cancerous) tumors. However, “benign” does not mean harmless; these tumors can grow, bleed, or impair kidney function, and having multiple AMLs warrants careful management [4]. A genetic counselor or medical geneticist can help you understand the genetic testing process, what the results mean, and how a diagnosis might impact your overall health and your family [5][1].

What Does the Genetic Test Look For?

Genetic testing for TSC typically involves taking a blood or saliva sample. The laboratory performs specialized reading (sequencing and deletion/duplication analysis) of two specific genes: TSC1 and TSC2 [6]. These genes normally help control cell growth, and when they are altered by a mutation, it can lead to the formation of tumors in various organs [7].

Understanding Your Results

Genetic testing for TSC is not always black and white. Here is what your results might show:

  • Positive result (Pathogenic variant found): A “pathogenic variant” is a mutation known to cause the disease. Finding one in either the TSC1 or TSC2 gene confirms a molecular diagnosis of TSC [6][8]. This confirms the diagnosis even if you do not currently have enough physical signs to meet the clinical criteria [9].
  • Negative result (No variant found): A negative blood test does not rule out TSC [10][11]. About 10% to 25% of people who meet the clinical criteria for TSC do not have a mutation identified on standard testing [12]. Some people have mosaicism (where the mutation is only in some cells of the body, not all of them), requiring high-depth testing or testing of a different tissue, like a skin sample, to detect it [13][14].
  • Variant of Uncertain Significance (VUS): Sometimes the test finds a change in the DNA, but scientists are not sure if it causes TSC or is just a harmless natural variation [15]. A VUS is neither a positive nor a negative result; it cannot be used to officially confirm a TSC diagnosis, guide major medical decisions, or confidently test other family members [16]. Over time, as more research is done, a VUS may be reclassified.

Clinical Diagnosis vs. Genetic Testing

You do not need a positive genetic test to be diagnosed with TSC. The International TSC Consensus guidelines state the condition can be diagnosed in two independent ways [17]:

  1. Genetic criteria: Finding a pathogenic TSC1 or TSC2 mutation [11].
  2. Clinical criteria: Having a specific combination of physical signs. To get a definite clinical diagnosis, you must have either two major features OR one major feature plus two minor features [3].

Having multiple renal AMLs counts as exactly one major feature. This means that AMLs alone do not prove you have TSC. However, if you also have another major feature—such as three or more specific white skin spots (hypomelanotic macules) or a lung condition called LAM—a specialist can make a clinically definite diagnosis even if your genetic test is negative [14][11].

Why Testing Matters: Screening Other Organs

If genetic testing (or a clinical evaluation) confirms TSC, it changes your medical care. TSC is a multisystem disease, meaning it can affect more than just your kidneys. A diagnosis triggers a systematic, lifelong, and highly individualized screening plan [3][18].

Depending on your age, sex, and specific symptoms, your medical team will likely recommend:

  • Kidney surveillance: Regular imaging (usually MRI every 1-3 years) to monitor AML growth and cysts, alongside routine blood pressure checks and kidney function tests [19][20].
  • Brain and Neurologic evaluations: Brain MRI schedules are tailored to your age and history of specific brain lesions. You will also be screened for seizures and TSC-Associated Neuropsychiatric Disorders (TAND), which include behavioral, developmental, and learning challenges [18][21].
  • Lung evaluations: Particularly for adult women, screening for a lung condition called lymphangioleiomyomatosis (LAM) using pulmonary function testing and chest CTs [22][23].
  • Skin and eye exams: Checking for specific rashes, spots, or retinal changes common in TSC [24][25].
  • Heart checks: Echocardiograms (an ultrasound of the heart) are often performed at baseline or in children to check for cardiac tumors [26].

Family Testing and Counseling

TSC is an autosomal dominant condition, meaning that inheriting just one altered copy of the gene can cause the disorder. However, many cases of TSC are de novo, meaning the mutation is brand new in the patient and was not inherited from a parent [7].

If you have a confirmed non-mosaic germline pathogenic variant, there is a 50% chance of passing it on to each child [7][27].

  • Testing relatives: A confirmed positive test allows your parents, siblings, and children to undergo targeted testing for that exact same mutation [7]. Predictive testing for family members is not done if you only have a VUS.
  • Family planning: Knowing your genetic status allows you to work with a genetic counselor to explore reproductive options, such as preimplantation or prenatal genetic testing [28][27].
  • Mosaicism complications: If you have mosaicism, counseling is highly individualized. The mutation might not show up in a standard blood test but could still be present in reproductive cells, altering the risks of passing it on [29][30].

Privacy and Insurance Considerations

Before proceeding with genetic testing, it is critical to discuss privacy and insurance with your genetic counselor or a local legal/insurance adviser. While health insurance and employment in many jurisdictions have protections against genetic discrimination, these laws often do not apply to life insurance, disability insurance, or long-term care insurance policies [31]. Knowing the specific protections and limitations in your local area beforehand can help you make the best decision for your situation.

Common questions in this guide

When should someone with kidney angiomyolipomas be evaluated for TSC?
Multiple or bilateral kidney angiomyolipomas are a strong reason to seek evaluation for tuberous sclerosis complex. A single isolated angiomyolipoma is common and does not by itself establish TSC, but a specialist or genetic counselor can assess your imaging and other findings.
What genes are tested for tuberous sclerosis complex?
Most TSC genetic tests analyze the TSC1 and TSC2 genes using a blood or saliva sample. Testing usually includes sequencing and deletion or duplication analysis to look for disease-causing changes.
Can a negative TSC genetic test rule out tuberous sclerosis?
No. Standard blood testing does not find a disease-causing change in about 10% to 25% of people who have enough clinical signs for TSC, and mosaicism can limit detection. A clinician may use physical exams, imaging, or testing of another tissue when suspicion remains.
What does a variant of uncertain significance mean?
It means the test found a DNA change whose medical importance is not known. It should not be treated as confirmation or exclusion of TSC, used to guide major medical decisions, or used for predictive testing of relatives; it may be reclassified later.
What happens if genetic testing confirms TSC?
A confirmed diagnosis usually leads to lifelong, individualized monitoring of the kidneys and other organs. Depending on age, sex, and findings, care may include kidney imaging and function tests, neurologic and brain assessments, lung screening, skin and eye exams, and heart checks.
Should relatives be tested if I have a TSC mutation?
If a confirmed, non-mosaic disease-causing TSC1 or TSC2 change is found, parents, siblings, and children may be offered targeted testing for the same change. A genetic counselor can explain inheritance, family planning, and whether testing is appropriate; a variant of uncertain significance should not be used for predictive family testing.

Related questions

How Long Should a Stable Renal Angiomyolipoma Be Monitored? What Growth Rate Is Fast for a Renal Angiomyolipoma? Can a Renal Angiomyolipoma Turn Into Kidney Cancer? Can I Exercise Safely with a Renal Angiomyolipoma? Can Blood Thinners Raise Renal Angiomyolipoma Bleeding Risk?
Show more
Is 4 cm Still the Treatment Cutoff for Renal Angiomyolipoma? Is MRI Better Than CT for Renal AML Surveillance Imaging? Small Sporadic Renal AML: How Often Should It Be Scanned? Can a Renal AML Cause Flank Pain Without Hematuria? Why Does an Angiomyolipoma Aneurysm Increase Bleeding Risk? Can a Small Renal Angiomyolipoma Rupture or Bleed? Do Multiple Bilateral AMLs Mean Tuberous Sclerosis? How Accurate Is a Biopsy for Fat-Poor AML vs Kidney Cancer? Is Ultrasound Reliable for Monitoring a Renal Angiomyolipoma? What Does Epithelioid Renal AML Mean? Can It Spread? What Happens During a Renal Mass Biopsy for Fat-Poor AML? What Do Classic, Fat-Poor, and Epithelioid Renal AMLs Mean? What Happens Next If a Fat-Poor Kidney AML Looks Cancerous? What Tests Are Needed for TSC After Finding a Kidney AML?

Get notified when new evidence is published on angiomyolipoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (31)
  1. 1

    Tuberous Sclerosis: Current Update.

    Wang MX, Segaran N, Bhalla S, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2021; (41(7)):1992-2010 doi:10.1148/rg.2021210103.

    PMID: 34534018
  2. 2

    Late-Onset Diagnosis of Tuberous Sclerosis Complex Revealed by Renal Angiomyolipoma: A Case Report.

    Fekih A, Heni W, Messaoudi C, et al.

    Clinical case reports 2026; (14(6)):e72928 doi:10.1002/ccr3.72928.

    PMID: 42339138
  3. 3

    Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.

    Northrup H, Aronow ME, Bebin EM, et al.

    Pediatric neurology 2021; (123()):50-66 doi:10.1016/j.pediatrneurol.2021.07.011.

    PMID: 34399110
  4. 4

    Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex.

    Buj Pradilla MJ, Martí Ballesté T, Torra R, Villacampa Aubá F

    Clinical kidney journal 2017; (10(6)):728-737 doi:10.1093/ckj/sfx094.

    PMID: 29225800
  5. 5

    Nervous system (NS) Tumors in Cancer Predisposition Syndromes.

    Patil P, Pencheva BB, Patil VM, Fangusaro J

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(6)):1752-1771 doi:10.1007/s13311-022-01277-w.

    PMID: 36056180
  6. 6

    A dermatological assessment of pediatric patients with tuberous sclerosis complex (TSC).

    Nunes BA, Romano AKFG, Pasa Morgan MA, et al.

    Anais brasileiros de dermatologia 2024; (99(5)):662-669 doi:10.1016/j.abd.2023.11.004.

    PMID: 38658236
  7. 7

    Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice.

    Peron A, Au KS, Northrup H

    American journal of medical genetics. Part C, Seminars in medical genetics 2018; (178(3)):281-290 doi:10.1002/ajmg.c.31651.

    PMID: 30255984
  8. 8

    Identification of a novel TSC1 gene variant in a patient with atypical vitiligo-like skin lesions: Unveiling the hidden tuberous sclerosis complex.

    Liu L, Wang Y, Zhang Z, et al.

    Molecular genetics & genomic medicine 2024; (12(3)):e2403 doi:10.1002/mgg3.2403.

    PMID: 38439608
  9. 9

    Ganglioglioma, Epilepsy, and Intellectual Impairment due to Familial TSC1 Deletion.

    Gilboa T, Segel R, Zeligson S, et al.

    Journal of child neurology 2018; (33(7)):482-486 doi:10.1177/0883073818767036.

    PMID: 29687738
  10. 10

    Deep phenotyping of patients with Tuberous Sclerosis Complex and no mutation identified in TSC1 and TSC2.

    Peron A, Vignoli A, Briola F, et al.

    European journal of medical genetics 2018; (61(7)):403-410 doi:10.1016/j.ejmg.2018.02.005.

    PMID: 29432982
  11. 11

    Tuberous sclerosis complex: review based on new diagnostic criteria.

    Portocarrero LKL, Quental KN, Samorano LP, et al.

    Anais brasileiros de dermatologia 2018; (93(3)):323-331 doi:10.1590/abd1806-4841.20186972.

    PMID: 29924239
  12. 12

    Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations.

    Nellist M, Brouwer RW, Kockx CE, et al.

    BMC medical genetics 2015; (16()):10 doi:10.1186/s12881-015-0155-4.

    PMID: 25927202
  13. 13

    Identification of a complex intrachromosomal inverted insertion in the long arm of chromosome 9 as a cause of tuberous sclerosis complex in a Korean family.

    Ryu SW, Yoon JH, Kim DW, et al.

    Molecular genetics & genomic medicine 2024; (12(3)):e2330 doi:10.1002/mgg3.2330.

    PMID: 38265426
  14. 14

    Targeted Genomic Sequencing of TSC1 and TSC2 Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal.

    West HD, Nellist M, Brouwer RWW, et al.

    Human mutation 2023; (2023()):4899372 doi:10.1155/2023/4899372.

    PMID: 40225170
  15. 15

    An overview of actionable and potentially actionable TSC1 and TSC2 germline variants in an online Database.

    Garcia ABM, Viola GD, Corrêa BDS, et al.

    Genetics and molecular biology 2024; (46(3 Suppl 1)):e20230132 doi:10.1590/1678-4685-GMB-2023-0132.

    PMID: 38373162
  16. 16

    Sequence Variants of Uncertain Significance: What to Do When Genetic Test Results Are Not Definitive.

    Greenblatt MS

    Surgical oncology clinics of North America 2015; (24(4)):833-46.

    PMID: 26363543
  17. 17

    Delayed Diagnosis of Tuberous Sclerosis Complex Presenting as Abnormal Uterine Bleeding: A Case Report and Literature Review.

    Bezabih KT, Belay HS, Kebede ML, et al.

    Clinical case reports 2026; (14(9)):e73438 doi:10.1002/ccr3.73438.

    PMID: 42699129
  18. 18

    [Tuberous sclerosis complex].

    Glutig K, Husain R, Renz D, et al.

    Radiologie (Heidelberg, Germany) 2022; (62(12)):1058-1066 doi:10.1007/s00117-022-01053-z.

    PMID: 35945379
  19. 19

    Renal manifestations of tuberous sclerosis complex: patients' and parents' knowledge and routines for renal follow-up - a questionnaire study.

    Cockerell I, Guenin M, Heimdal K, et al.

    BMC nephrology 2018; (19(1)):39 doi:10.1186/s12882-018-0835-3.

    PMID: 29439672
  20. 20

    Blood pressure and glomerular filtration rate in youth with tuberous sclerosis complex.

    Vargiami E, Stabouli S, Sidira C, et al.

    European journal of pediatrics 2022; (181(4)):1465-1472 doi:10.1007/s00431-021-04333-3.

    PMID: 34988664
  21. 21

    Tuberous sclerosis complex: Diagnostic features, surveillance, and therapeutic strategies.

    Arredondo KH, Jülich K, Roach ES

    Seminars in pediatric neurology 2024; (51()):101155 doi:10.1016/j.spen.2024.101155.

    PMID: 39389658
  22. 22

    Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.

    von Ranke FM, Zanetti G, e Silva JL, et al.

    Lung 2015; (193(5)):619-27 doi:10.1007/s00408-015-9750-6.

    PMID: 26104489
  23. 23

    [IMPORTANCE OF SCREENING FOR LUNG LYMPHANGIOLEIOMYOMATOSIS AMONG RENAL ANGIOMYOLIPOMA CASES].

    Sakaguchi K, Oka S, Ogawa K, et al.

    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 2017; (108(4)):188-193 doi:10.5980/jpnjurol.108.188.

    PMID: 30333440
  24. 24

    Ophthalmic manifestations of tuberous sclerosis: a review.

    Hodgson N, Kinori M, Goldbaum MH, Robbins SL

    Clinical & experimental ophthalmology 2017; (45(1)):81-86 doi:10.1111/ceo.12806.

    PMID: 27447981
  25. 25

    Challenges of siblings with tuberous sclerosis showing various manifestations and severe complications.

    Purbasari U, Prihartono NA, Helda N, et al.

    Radiology case reports 2024; (19(6)):2566-2573 doi:10.1016/j.radcr.2024.03.002.

    PMID: 38596180
  26. 26

    A Review of Investigations for Patients With Tuberous Sclerosis Complex Who Were Referred to the Tuberous Sclerosis Clinic at The Hospital for Sick Children: Identifying Gaps in Surveillance.

    Alsowat D, Zak M, McCoy B, et al.

    Pediatric neurology 2020; (102()):44-48 doi:10.1016/j.pediatrneurol.2019.06.018.

    PMID: 31362847
  27. 27

    The genetics and diagnosis of pediatric neurocutaneous disorders: Neurofibromatosis and tuberous sclerosis complex.

    Tolliver S, Smith ZI, Silverberg N

    Clinics in dermatology 2022; (40(4)):374-382 doi:10.1016/j.clindermatol.2022.02.010.

    PMID: 35248688
  28. 28

    Diagnosis of tuberous sclerosis complex in the fetus.

    Dragoumi P, O'Callaghan F, Zafeiriou DI

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(6)):1027-1034 doi:10.1016/j.ejpn.2018.08.005.

    PMID: 30279084
  29. 29

    Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission.

    Giannikou K, Lasseter KD, Grevelink JM, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(11)):2639-2643 doi:10.1038/s41436-019-0562-6.

    PMID: 31160751
  30. 30

    Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.

    Tyburczy ME, Dies KA, Glass J, et al.

    PLoS genetics 2015; (11(11)):e1005637 doi:10.1371/journal.pgen.1005637.

    PMID: 26540169
  31. 31

    Developing the MyCancerGene Digital Health Portal to Improve Patients' Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study.

    Trieu P, Fetzer D, McLeod B, et al.

    JMIR formative research 2025; (9()):e56282 doi:10.2196/56282.

    PMID: 40366732

This page is for informational purposes only and does not constitute medical advice. A genetic counselor or qualified clinician can help determine whether TSC testing is appropriate and explain what your results mean.